ArticleCancer gene therapy2024

LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling.

Shaobo Yu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.